Earnings ·
Reports Q3 net loss of $0.08 per share; cash runway extends into fourth quarter 2027
TNYATenaya Therapeutics, Inc.
Tenaya Therapeutics reported a third-quarter net loss of $18.9 million, or $0.08 per share, compared to a $20.3 million loss in the prior-year period. Research and development expenses decreased to $14.9 million from $15.4 million, while general and administrative costs remained flat at $5.6 million. The company holds $66.8 million in cash and cash equivalents as of September 30, 2026, which management expects will fund operations into the fourth quarter of 2027. Additionally, Tenaya provided updates on its gene therapy programs TN-201 and TN-401, noting that it plans to report longer-term clinical data and regulatory feedback by year-end. The company operates as a clinical-stage biotechnology firm focused on discovering and developing curative therapies for heart disease.